Evoke Pharma Inc. (NASDAQ:EVOK) shares fell 6.4% on Tuesday . The company traded as low as $2.40 and last traded at $2.48, with a volume of 1,407,206 shares changing hands. The stock had previously closed at $2.65.

A number of brokerages have recently weighed in on EVOK. Rodman & Renshaw cut Evoke Pharma from a “buy” rating to a “neutral” rating and set a $2.00 price target for the company. in a research report on Monday, July 18th. Brean Capital cut Evoke Pharma from a “buy” rating to a “hold” rating in a research report on Monday, July 18th. FBR & Co restated a “buy” rating on shares of Evoke Pharma in a research report on Friday, July 8th. Finally, Zacks Investment Research cut Evoke Pharma from a “buy” rating to a “hold” rating in a research report on Monday, May 16th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and three have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $13.34.

The stock has a 50 day moving average price of $5.75 and a 200 day moving average price of $4.76. The firm’s market cap is $18.17 million.

Evoke Pharma (NASDAQ:EVOK) last announced its quarterly earnings results on Wednesday, May 11th. The specialty pharmaceutical company reported ($0.45) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.41) by $0.04. On average, equities research analysts predict that Evoke Pharma Inc. will post ($1.43) earnings per share for the current year.

In other Evoke Pharma news, major shareholder Parters Vii L. P. Domain sold 344,120 shares of the business’s stock in a transaction on Thursday, May 26th. The stock was sold at an average price of $4.70, for a total transaction of $1,617,364.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.